Kineta to Present at Symposium on Next-Generation Therapeutics for the Treatment of Pain
Seattle, WA, April 25, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced Kineta CEO Shawn Iadonato has been invited to present at the Next-Generation Therapeutics for the Treatment of Pain Symposium sponsored by Life Science Washington. This Symposium will be held on April 27, 2017 from 3:30-6:30 PM PST at the Agora Conference Center in Seattle, WA.
Dr. Iadonato will present preclinical data on the disease modifying effects of KCP-400, a novel non-opioid in development for the treatment of chronic pain. This first in class therapeutic has demonstrated robust analgesic, anti-inflammatory and neuroprotective effects in multiple pain models.
This symposium will discuss several innovative therapeutic approaches based on novel pain targets and mechanisms, as well as review new clinical approaches for development. Click Here to learn more about this event.
Kineta, Inc. is an emerging biotech company that fills a void in the biopharmaceutical industry by efficiently advancing first in class immuno-therapies from discovery to proof of concept. Kineta is developing a focused pipeline of novel therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. We actively collaborate with a broad array of private, government, biodefense and industry partners to advance our innovative research. For more information on Kineta, Inc. visit our website, www.kinetabio.com
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.